ES2114184T3 - Composicion a base de microparticulas en fase condensada y procedimiento. - Google Patents

Composicion a base de microparticulas en fase condensada y procedimiento.

Info

Publication number
ES2114184T3
ES2114184T3 ES94909762T ES94909762T ES2114184T3 ES 2114184 T3 ES2114184 T3 ES 2114184T3 ES 94909762 T ES94909762 T ES 94909762T ES 94909762 T ES94909762 T ES 94909762T ES 2114184 T3 ES2114184 T3 ES 2114184T3
Authority
ES
Spain
Prior art keywords
procedure
composition based
condensed phase
phase microparticles
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94909762T
Other languages
English (en)
Inventor
Julio M Fernandez
Mark B Knudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2114184T3 publication Critical patent/ES2114184T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN UNA COMPOSICION DE MICROPARTICULAS ENCAPSULADAS Y SU METODO DE USO EN APLICACIONES DE ADMINISTRACION DE FARMACOS Y DE DIAGNOSTICO. TAMBIEN SE PRESENTAN LOS METODOS PARA CONSERVAR Y ADMINISTRAR COMPUESTOS DE FARMACOS A UN ALTO NIVEL DE CONCENTRACION EN MICROPARTICULAS DE FASE CONDENSADA.
ES94909762T 1993-02-12 1994-02-10 Composicion a base de microparticulas en fase condensada y procedimiento. Expired - Lifetime ES2114184T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1768193A 1993-02-12 1993-02-12
PCT/US1994/001924 WO1994017786A1 (en) 1993-02-12 1994-02-10 Condensed-phase microparticle composition and method

Publications (1)

Publication Number Publication Date
ES2114184T3 true ES2114184T3 (es) 1998-05-16

Family

ID=21783984

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94909762T Expired - Lifetime ES2114184T3 (es) 1993-02-12 1994-02-10 Composicion a base de microparticulas en fase condensada y procedimiento.

Country Status (9)

Country Link
EP (1) EP0684812B1 (es)
JP (1) JPH08509956A (es)
AT (1) ATE162397T1 (es)
AU (1) AU676543B2 (es)
CA (1) CA2155648C (es)
DE (1) DE69408122T2 (es)
DK (1) DK0684812T3 (es)
ES (1) ES2114184T3 (es)
WO (1) WO1994017786A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
EP0769063A1 (en) * 1994-06-27 1997-04-23 The Johns Hopkins University Targeted gene delivery system
AU3739697A (en) * 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
ES2317657T3 (es) 1996-09-19 2009-04-16 The Regents Of The University Of Michigan Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados.
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
ATE430199T1 (de) 1998-01-31 2009-05-15 Univ Arkansas Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
DE19943429A1 (de) * 1999-09-08 2001-03-15 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an sulfonierten Kammpolymeren
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI84874C (fi) * 1989-11-02 1992-02-10 Valio Meijerien Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den.
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.

Also Published As

Publication number Publication date
ATE162397T1 (de) 1998-02-15
DE69408122T2 (de) 1998-09-03
AU6247994A (en) 1994-08-29
AU676543B2 (en) 1997-03-13
WO1994017786A1 (en) 1994-08-18
JPH08509956A (ja) 1996-10-22
DK0684812T3 (da) 1998-09-21
EP0684812A1 (en) 1995-12-06
EP0684812B1 (en) 1998-01-21
DE69408122D1 (de) 1998-02-26
CA2155648A1 (en) 1994-08-18
CA2155648C (en) 1999-05-11

Similar Documents

Publication Publication Date Title
ATE183387T1 (de) Pharmazeutische und andere darreichungsformen
ATE204467T1 (de) Orale darreichungsform
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
AU7405387A (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DE69426984D1 (de) Arzneizubereitung
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
NO904754D0 (no) Kapsel for innkapsling av biologisk aktive materialer, fremgangsmaate for fremstilling av denne, samt anvendelse derav.
DE69408122D1 (de) Zusammensetzung aus mikropartikeln in verdichteter phase und verfahren
DE60019334D1 (de) Antivirale arznei
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE69427485D1 (de) Verbindungen, zubereitungen und behandlung von allergien und entzündungen
FR2768341B1 (fr) Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
SE8800080D0 (sv) Lekemedelskomposition
EE03205B1 (et) Ropivakaiini kasutamine valuvaigistina kasutatava ravimpreparaadi valmistamiseks
AR019331A2 (es) Composicion farmaceutica que contiene un sensibilizador a insulina y un secretagogo de insulina.
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
FR2701847B1 (fr) Compositions pharmaceutiques et cosmétiques à base d'albumine végétale, préparations contenant de telles compositions et procédé de préparation.
AU9221898A (en) Pharmaceutical coating composition and method of use
EA200200234A1 (ru) Препараты для парентерального применения эстрамустин фосфата и альбумина
NO302360B1 (no) NG-monometyl-L-argininhydrokloridderivater
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 684812

Country of ref document: ES